Persistent fatigue remains a five-year burden after prostate radiotherapy
Long-term fatigue did not fade quickly for many men treated with radiotherapy for non-metastatic prostate cancer. In the international REQUITE cohort, clinically important fatigue appeared at least once in about 35% of 1,758 men from the start of radiotherapy through five years of follow-up, and 14% still reported fatigue two years after treatment. For a symptom often treated as transient or secondary to acute toxicity, the persistence matters at the bedside: fatigue can shape recovery, physical function, adherence to follow-up, and a patient’s willingness to tolerate future therapy.
The data also point to a familiar but often underappreciated pattern in oncology. Fatigue rarely travels alone. Men with long-term fatigue were much more likely to report pain, insomnia, pelvic symptoms, functional impairment, and poorer quality of life, suggesting that fatigue may sit at the center of a broader symptom cluster rather than functioning as an isolated complaint. In prostate cancer care, where radiotherapy is commonly delivered with curative intent, that cluster can define survivorship just as much as the tumor response does.
Baseline fatigue and diabetes identified a higher-risk subgroup
Before radiotherapy even began, some men were already carrying a heavier symptom load. Pre-radiotherapy fatigue was the strongest predictor of clinically important fatigue two years later, with an odds ratio of 8.67. Self-reported diabetes also predicted worse fatigue outcomes, alongside age and body mass index, with odds ratios of 1.94, 1.03, and 1.07, respectively.
One sentence captures the clinical message clearly: men who start treatment already tired are the ones most likely to remain tired.
Diabetes is especially plausible as a modifier of long-term fatigue because it can compound metabolic stress, inflammation, and vascular dysfunction, all of which may worsen energy balance and physical resilience during and after cancer therapy. Higher body mass index may operate through a similar web of mechanisms, including reduced exercise tolerance, chronic inflammatory signaling, sleep disruption, and greater burden from comorbid disease. Age, although a modest predictor on a per-unit basis, adds to the cumulative risk profile. The study does not suggest that any single factor explains the symptom course on its own; rather, fatigue appears to emerge from the interaction of baseline vulnerability and treatment-related stress.
Four fatigue trajectories separated men into distinct recovery patterns
Latent class growth analysis identified four distinct fatigue trajectories over time. The largest groups were low fatigue, comprising 45% of men, and moderate fatigue, comprising 42%. Two smaller groups followed less favorable courses: 8% showed elevated but decreasing fatigue, while 6% had increasing fatigue over time.
Those trajectory patterns are clinically important because they show that prostate cancer survivors are not moving through one shared recovery curve. Some men experience a gradual easing of symptoms after treatment ends, while others drift into a worsening course that may only become obvious when follow-up is structured and repeated. Diabetes increased the probability of belonging to the increasing fatigue trajectory by 6 percentage points, reinforcing the need to treat metabolic comorbidity as more than background noise in survivorship care.
The pattern also argues against relying on a single post-treatment visit to judge recovery. A man who looks stable at the end of radiotherapy may still slide into persistent or worsening fatigue over the following years. Repeated patient-reported outcome collection is what exposes that drift.
What the symptom pattern means for radiotherapy follow-up
The EORTC QLQ-C30 made it possible to track fatigue as a patient-reported outcome rather than a vague clinical impression. That matters because fatigue is subjective, but it is not imprecise. The questionnaire captures how much rest a patient needs and how weak or tired he felt during the prior week, then converts those responses into standardized scores from 0 to 100. In this cohort, clinically important fatigue was defined using established thresholds, allowing the investigators to distinguish a meaningful symptom burden from background variation.
The stronger signal came from the broader symptom network. Men with long-term fatigue also reported worse functioning and poorer global quality of life, which is exactly what clinicians see when fatigue has crossed from a nuisance into a driver of disability. In practice, that can mean less walking, less exercise, lower mood, and more difficulty managing other treatment effects. Fatigue then becomes self-reinforcing: reduced activity worsens deconditioning, deconditioning worsens fatigue, and sleep disruption or pain further erodes recovery.
A case for risk-stratified aftercare
The practical implication is not simply to ask about fatigue more often. It is to identify which men are most likely to need active follow-up before the symptom becomes entrenched. The strongest pre-treatment signals in this cohort were already present before the first radiotherapy fraction: baseline fatigue, diabetes, higher body mass index, and older age. Those variables are easy to measure and do not require exotic biomarker testing.
In a curative prostate radiotherapy program, that could support a tiered follow-up approach. Men with elevated baseline fatigue or diabetes may warrant closer symptom surveillance, earlier supportive care, and lower thresholds for evaluating sleep disturbance, pain, pelvic toxicity, or reduced physical functioning. The study does not specify a single intervention that will prevent long-term fatigue, but it makes the target population much easier to define.
The absence of a simple one-size-fits-all explanation is part of the value here. Fatigue after prostate radiotherapy is not merely an acute side effect that lingers by chance. In a substantial minority of men, it follows a detectable trajectory, and the earliest clue is often already in the chart before treatment starts. The unresolved challenge is how best to intervene once those warning signs are present, and how to integrate symptom monitoring into routine prostate cancer aftercare without waiting for fatigue to become a chronic disability.